

Pharmacia & Upjohn

Agent ID# 56248

TUCOPRIM® Powder MATERIAL SAFETY DATA SHEET

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

COMMON NAME: TUCOPRIM® Powder
MOLECULAR FORMULA: Mixture
CHEMICAL FAMILY: Antibiotic
USE: Veterinary product for bacterial infections in equine. Not for human use.
MANUFACTURER/SUPPLIER:
PHARMACIA & UPJOHN CO., A SUBSIDIARY OF
PHARMACIA CORP.
7171 PORTAGE RD
KALAMAZOO, MI 49001-0199
TELEPHONE NUMBERS:
(616) 833-5122 - (24 Hours)
(616) 833-7555 - (8:00 AM - 4:30 PM, EST)

2. COMPOSITION/INFORMATION ON INGREDIENTS

INGREDIENT 1

COMMON NAME: Calcium Carbonate
% BY WEIGHT: 60 %
CAS NUMBER: 471-34-1
EXPOSURE LIMIT(S): OSHA PEL-TWA: 15 mg/m³
ACGIH TLV-TWA: 10 mg/m³

INGREDIENT 2

COMMON NAME: Trimethoprim
% BY WEIGHT: 33.3 %
CAS NUMBER: 738-70-5
EXPOSURE LIMIT(S): PHARMACIA & UPJOHN
EXPOSURE LIMIT-TWA: 0.1 mg/m³

INGREDIENT 3

COMMON NAME: Sulfadiazine
% BY WEIGHT: 6.7 %
CAS NUMBER: 68-35-9
EXPOSURE LIMIT(S): PHARMACIA & UPJOHN
EXPOSURE LIMIT-TWA: 2 mg/m³

EXPOSURE LIMIT(S) FOR THE MATERIAL: Not established.

3. HAZARDS IDENTIFICATION

PRIMARY ROUTE(S) OF EXPOSURE: Skin contact, eye contact, ingestion, and inhalation.
EFFECTS OF OVEREXPOSURE: May cause allergic skin reactions. Overexposure may cause nausea, vomiting, cramps, diarrhea and colitis.

MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: Hypersensitivity to trimethoprim or sulfadiazine.

4. FIRST AID MEASURES

EYES: Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes.
SKIN: Wash off with soap and water. Take off all contaminated clothing immediately.
INHALATION: Move to fresh air.
INGESTION: Contact a physician or poison control center.

5. FIRE FIGHTING MEASURES

FLASH POINT: Not applicable (solid).
LOWER EXPLOSION LIMIT (LEL): Not applicable.
UPPER EXPLOSION LIMIT (UEL): Not applicable.
EXTINGUISHING MEDIA: Water, carbon dioxide or dry chemical.
FIRE FIGHTING PROCEDURES: Wear self-contained breathing apparatus and full-body protective equipment.
UNUSUAL FIRE OR EXPLOSION HAZARDS: As with all finely divided organic powders, it is advisable to eliminate explosion hazards by methods such as grounding mechanical equipment in contact with the material to prevent the buildup of static electricity, inerting the atmosphere or controlling dust levels.
HAZARDOUS COMBUSTION PRODUCTS: Carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides.

6. ACCIDENTAL RELEASE MEASURES

STEPS TO BE TAKEN IN CASE MATERIAL IS RELEASED OR SPILLED: Remove all sources of ignition. Control the generation of dust/vapors. Ensure adequate ventilation. Provide respiratory, skin and eye protection to prevent over-exposure. Do not let product enter drains. Do not flush into surface water. Do not flush to groundwater and soil. Vacuum with HEPA-filtered and explosion-proof equipment. Shovel into suitable container for disposal.

7. HANDLING AND STORAGE

PRECAUTIONS FOR HANDLING AND STORING: Avoid generating dust/vapors and contact with skin, eyes and clothing. Use with adequate ventilation. Wash thoroughly after handling. Launder contaminated clothing before reuse. Store at room temperature. Do not get in eyes, on skin or clothing. Avoid breathing dust or mist. Use adequate dust/vapor control. Keep out of reach of children.

8. EXPOSURE CONTROLS/ PERSONAL PROTECTION

RESPIRATORY PROTECTION: Not required.
VENTILATION: Local exhaust.
PROTECTIVE GLOVES: Not required.
EYE PROTECTION: Not required.
OTHER PROTECTIVE EQUIPMENT: Not required.

9. PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE/PHYSICAL STATE: White to off-white powder.
MOLECULAR WEIGHT: Mixture.

10. STABILITY AND REACTIVITY

STABILITY: Stable.
PHYSICAL CONDITIONS TO AVOID: None.
INCOMPATIBILITY WITH OTHER MATERIALS: None.
HAZARDOUS DECOMPOSITION PRODUCTS: None.
HAZARDOUS POLYMERIZATION: Does not occur.

11. TOXICOLOGICAL INFORMATION

ACUTE STUDIES:
SENSITIZATION: May cause hypersensitivity reactions.
ORAL LD50 (RAT): Greater than 5 g/kg for trimethoprim/sulfadiazine.
ORAL LD50 (MOUSE): Greater than 5 g/kg for trimethoprim/sulfadiazine.
OTHER STUDIES:
CARCINOGENICITY: Ingredient(s) are not listed as carcinogenic by IARC, NTP or OSHA.

12. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHOD: Dispose of by incineration in accordance with applicable international, national, state and/or local waste disposal regulations.

13. SHIPPING REGULATIONS

Not regulated for transportation by the United States Department of Transportation (DOT), International Maritime Organization (IMO), or International Air Transport Association (IATA). May be subject to state and/or local transportation requirements.

14. OTHER INFORMATION

REVIEWED BY: Environment & Safety.
DISCLAIMER: The information contained in the MSDS is believed to be correct as of its date of issuance. BY MAKING THE MSDS AVAILABLE, PHARMACIA & UPJOHN DOES NOT MAKE ANY EXPRESS OR IMPLIED WARRANTY (INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE) REGARDING THE MSDS, ITS ACCURACY OR THE PRODUCT TO WHICH IT RELATES. Anyone using this information agrees that Pharmacia & Upjohn shall not be held liable (based on its negligence or otherwise) for any personal injury or other damage relating to, or arising from such use, including direct, incidental, or consequential damage and such user agrees to indemnify Pharmacia & Upjohn for any claims arising out of its use.

15. LABELING

This drug is subject to FDA labeling requirements; therefore, it is exempt from the labeling requirements of the OSHA Hazard Communication Standard.

NDC 0009-7703-01
NDC 0009-7703-02

December 15, 1999